cell encapsulation possible solution graft rejection tissue engineering applications cell microencapsulation technology involves immobilization cells within polymeric semipermeable membrane permits bidirectional diffusion molecules influx oxygen nutrients growth factors etc essential cell metabolism outward diffusion waste products therapeutic proteins time semipermeable nature membrane prevents immune cells antibodies destroying encapsulated cells regarding foreign invaders cell encapsulation could reduce need longterm use immunosuppressive drugs organ transplant control side effects vincenzo bisceglie made first attempt encapsulate cells polymer membranes demonstrated tumor cells polymer structure transplanted pig abdominal cavity remained viable long period without rejected immune thirty years later idea encapsulating cells within ultra thin polymer membrane microcapsules provide immunoprotection cells proposed thomas chang introduced term artificial cells define concept suggested artificial cells produced drop method protected encapsulated cells immunorejection also provided high surfacetovolume relationship enabling good mass transfer oxygen twenty years later approach successfully put practice small animal models alginatepolylysinealginate apa microcapsules immobilizing xenograft islet cells study demonstrated microencapsulated islets implanted diabetic rats cells remained viable controlled glucose levels several weeks human trials utilising encapsulated cells performed encapsulated cells expressing cytochrome enzyme locally activate antitumour prodrug used trial advanced nonresectable pancreatic cancer approximately doubling survival time compared historic controls demonstrated questions could arise technique encapsulation cells even required therapeutic products could injected site important reason encapsulated cells would provide source sustained continuous release therapeutic products longer durations site implantation another advantage cell microencapsulation technology allows loading nonhuman genetically modified cells polymer matrix availability donor cells microencapsulation valuable technique local regional oral delivery therapeutic products implanted numerous tissue types organs prolonged drug delivery treatment site implantation drug loaded artificial cells would cost effective comparison direct drug delivery moreover prospect implanting artificial cells similar chemical composition several patients irrespective leukocyte antigen could allow reduction potential using cell microencapsulation successful clinical applications realized several requirements encountered development process optimized use appropriate biocompatible polymer form mechanically chemically stable semipermeable matrix production uniformly sized microcapsules use appropriate immunecompatible polycations crosslinked encapsulation polymer stabilized capsules selection suitable cell type depending situation use best biomaterial depending application crucial development drug delivery systems tissue engineering polymer alginate commonly used due early discovery easy availability low cost materials cellulose sulphate collagen chitosan gelatin agarose also employed several groups extensively studied several natural synthetic polymers goal developing suitable biomaterial cell extensive work done using alginates regarded suitable biomaterials cell microencapsulation due abundance excellent biocompatibility biodegradability properties alginate natural polymer extracted seaweed numerous compositions based isolation alginate free criticism researchers believe alginates highm content could produce inflammatory abnormal cell demonstrated alginate highg content lead even higher cell inflammatory reaction vivo compared intermediateg even ultrapure alginates may contain endotoxins polyphenols could compromise biocompatibility resultant cell shown even though purification processes successfully lower endotoxin polyphenol content processed alginate difficult lower protein purification processes could turn modify properties thus essential effective purification process designed remove contaminants alginate successfully used clinical applications researchers also able develop alginate microcapsules altered form alginate enhanced biocompatibility higher resistance osmotic another approach increasing biocompatibility membrane biomaterial surface modification capsules using peptide protein molecules turn controls proliferation rate differentiation encapsulated cells one group working extensively coupling amino acid sequence argglyasp rgd alginate hydrogels demonstrated cell behavior controlled rgd density coupled alginate gels alginate microparticles loaded myoblast cells functionalized rgd allowed control growth differentiation loaded another vital factor controls use cell microcapsules clinical applications development suitable immunecompatible polycation coat otherwise highly porous alginate beads thus impart stability immune protection polyllysine commonly used polycation low biocompatibility restricts successful clinical use pll formulated microcapsules attract inflammatory cells thus inducing necrosis loaded studies also shown alginatepllalginate apa microcapsules demonstrate low mechanical stability short term durability thus several research groups looking alternatives pll demonstrated promising results polymethylenecoguanidine fabricating durable microcapsules high controlled mechanical strength cell encapsulation several groups also investigated use chitosan naturally derived polycation potential replacement pll fabricate alginatechitosan ac microcapsules cell delivery however studies also shown stability ac membrane one group demonstrated modification alginatechitosan microcapsules genipin naturally occurring iridoid glucosid gardenia fruits form genipin crosslinked alginatechitosan gcac microcapsules could augment stability cell loaded collagen major protein component ecm provides support tissues like skin cartilage bones blood vessels ligaments thus considered model scaffold matrix tissue engineering due properties biocompatibility biodegradability ability promote cell ability allows chitosan control distribution cells inside polymeric system thus typei collagen obtained animal tissues successfully used commercially tissue engineered biomaterial multiple collagen also used nerve bladder immunogenicity limited applications collagen gelatin considered alternative gelatin prepared denaturation collagen many desirable properties biodegradability biocompatibility nonimmunogenity physiological environments easy processability make polymer good choice tissue engineering used engineering tissues skin bone cartilage used commercially skin chitosan polysaccharide composed randomly distributed dglucosamine deacetylated unit nacetyldglucosamine acetylated unit derived ndeacetylation chitin used several applications drug spacefilling wound however one drawback polymer weak mechanical properties thus often combined polymers collagen form polymer stronger mechanical properties cell encapsulation agarose polysaccharide derived seaweed used nanoencapsulation cells cellagarose modified form microbeads reducing temperature however one drawback microbeads obtained possibility cellular protrusion polymeric matrix wall formation capsules cellulose sulphate derived cotton processed appropriately used biocompatible base suspend cells polyanionic cellulose sulphate solution immersed second polycationic solution eg pdadmac semipermeable membrane formed around suspended cells result gelation two polyions mammalian cell lines bacterial cells remain viable continue replicate within capsule membrane order fillout capsule contrast encapsulation materials capsules used grow cells act like minibioreactor biocompatible nature material demonstrated observation studies using cellfilled capsules implantation well isolated capsule capsules formed cellulose sulphate successfully used showing safety efficacy clinical preclinical trials humans animals primarily anticancer treatments also exploring possible uses gene therapy antibody using cellulose sulphate possible manufacture encapsulated cells pharmaceutical product large scale fulfilling good manufacturing process cgmp standards achieved company austrianova use ideal high quality biomaterial inherent properties biocompatibility crucial factor governs long term efficiency technology ideal biomaterial cell encapsulation one totally biocompatible trigger immune response host interfere cell homeostasis ensure high cell however one major limitation inability reproduce different biomaterials requirements obtain better understanding chemistry biofunctionality biomaterials microencapsulation several studies demonstrate surface modification cell containing microparticles allows control growth cellular encapsulated one study proposed use zeta potential measures electric charge microcapsule means predict interfacial reaction microcapsule surrounding tissue turn biocompatibility delivery fundamental criterion must established developing device semipermeable membrane adjust permeability device terms entry exit essential cell microcapsule designed uniform thickness control rate molecules entering capsule necessary cell viability rate therapeutic products waste material exiting capsule membrane immunoprotection loaded cell key issue must kept mind working permeability encapsulation membrane immune cells also antibodies cytokines prevented entry microcapsule fact depends pore size shown since different cell types different metabolic requirements thus depending cell type encapsulated membrane permeability membrane several groups dedicated towards study membrane permeability cell although role permeability certain essential elements like oxygen permeability requirements cell type yet determined sodium citrate used degradation alginate beads encapsulation order determine viability cells experimentation concentrations approximately used dissolve alginate spheres solution spun using centrifuge sodium citrate removed cells collected essential microcapsules adequate membrane strength mechanical stability endure physical osmotic stress exchange nutrients waste products microcapsules strong enough rupture implantation could lead immune rejection encapsulated instance case xenotransplantation tighter stable membrane would required comparison allotransplantation also investigating potential using apa microcapsules loaded bile salt hydrolase bsh overproducing active lactobacillus plantarum cells simulated gastro intestinal tract model oral delivery applications mechanical integrity shape microcapsules evaluated shown apa microcapsules could potentially used oral delivery live bacterial however research proved gcac microcapsules possess higher mechanical stability compared apa microcapsules oral delivery martoni et al experimenting bacteriafilled capsules would taken mouth reduce serum cholesterol capsules pumped series vessels simulating human gi tract determine well capsules would survive body extensive research mechanical properties biomaterial used cell microencapsulation necessary determine durability microcapsules production especially vivo applications sustained release therapeutic product long durations required van der wijngaart et grafted solid permeable shell around cells provide increased mechanical strength sodium citrate used degradation alginate beads encapsulation order determine viability cells experimentation concentrations approximately used dissolve alginate spheres solution spun using centrifuge sodium citrate removed cells collected dropletbased microfluidics used generate microparticles repeatable eletrospraying used create alginate spheres pumping alginate solution needle source high voltage usually provided clamp attached needle used generate electric potential alginate falling needle tip solution contains ground calcium chloride used cross linking solution generated capsules drop harden approximately minutes beads formed needle due charge surface diameter microcapsules important factor influences immune response towards cell microcapsules well mass transport across capsule membrane studies show cellular response smaller capsules much lesser compared larger general diameter cell loaded microcapsules µm enable effective diffusion across semipermeable cell type chosen technique depends desired application cell microcapsules cells put capsules patient autologous cells another donor allogeneic cells species xenogeneic use autologous cells microencapsulation therapy limited availability cells even though xenogeneic cells easily accessible danger possible transmission viruses especially porcine endogenous retrovirus patient restricts clinical much debate several groups concluded studies involve use allogeneic instead xenogeneic depending application cells genetically altered express required however enough research carried validate safety stability expressed gene types cells used technology received approval clinical trial high immunogenicity cells loaded capsules secrete cytokines produce severe inflammatory reaction implantation site around capsules turn leading decrease viability encapsulated one promising approach studied administration antiinflammatory drugs reduce immune response produced due administration cell loaded another approach focus extensive research use stem cells mesenchymal stem cells long term cell microencapsulation cell therapy applications hopes reducing immune response patient another issue compromises long term viability microencapsulated cells use fast proliferating cell lines eventually fill entire system lead decrease diffusion efficiency across semipermeable membrane solution could use cell types myoblasts proliferate microencapsulation procedure probiotics increasingly used numerous dairy products ice cream milk powders yoghurts frozen dairy desserts cheese due important health benefits low viability probiotic bacteria food still remains major hurdle ph dissolved oxygen content titratable acidity storage temperature species strains associative fermented dairy product organisms concentration lactic acetic acids factors greatly affect probiotic viability set food agriculture organization fao united nations world health organization standard order considered health food probiotic addition product contain per gram least cfu viable probiotic necessary bacterial cells remain stable healthy manufactured product sufficiently viable moving upper digestive tract able provide positive effects upon reaching intestine cell microencapsulation technology successfully applied food industry encapsulation live probiotic bacteria cells increase viability bacteria processing dairy products targeted delivery gastrointestinal apart dairy products microencapsulated probiotics also used nondairy products theresweettm sweetener used convenient vehicle delivery encapsulated lactobacillus intestine although dairy product potential using bioartificial pancreas treatment diabetes mellitus based encapsulating islet cells within semi permeable membrane extensively studied scientists devices could eliminate need immunosuppressive drugs addition finally solving problem shortage organ donors use microencapsulation would protect islet cells immune rejection well allow use animal cells genetically modified insulinproducing hoped development islet encapsulated microcapsules could prevent need insulin injections needed several times day type diabetic edmonton protocol involves implantation human islets extracted cadaveric donors shown improvements towards treatment type diabetics prone hypoglycemic however two major hurdles faced technique limited availability donor organs need immunosuppresents prevent immune response patients body several studies dedicated towards development bioartificial pancreas involving immobilization islets langerhans inside polymeric capsules first attempt towards aim demonstrated lim et al xenograft islet cells encapsulated inside alginate polylysine microcapsules showed significant vivo results several envisaged implantation encapsulated cells would help overcome use immunosuppressive drugs also allow use xenograft cells thus obviating problem donor shortage polymers used islet microencapsulation polyethylene glycol sodium cellulose sulfate waterinsoluble polyacrylates alginate peg commonly used polymers successful vitro studies performed using technique significant work clinical trials using microencapsulated human islets carried use alginateplo microcapsules containing islet cells pilot clinical trials permitted carried university perugia italian ministry another study potential clinical application pegylation low doses immunosuppressant cyclosporine evaluated trial began novocell forms phase iii clinical trials involving implantation islet allografts subcutaneous however controversial studies involving human clinical trials living cell technologies ltd demonstrated survival functional xenogeneic cells transplanted without immunosuppressive medication however trial received harsh criticism international xenotransplantation association risky however even though clinical trials way several major issues biocompatibility immunoprotection need potential alternatives encapsulating isolated islets either allo xenogeneic origin also explored using sodium cellulose sulphate technology austrianova singapore islet cell line encapsulated demonstrated cells remain viable release insulin response preclinical studies implanted encapsulated cells able restore blood glucose levels diabetic rats period use cell encapsulated microcapsules towards treatment several forms cancer shown great potential one approach undertaken researchers implantation microcapsules containing genetically modified cytokine secreting cells example demonstrated cirone et al genetically modified cytokine secreting nonautologous mouse myoblasts implanted mice showed delay tumor growth increased rate survival however efficiency treatment brief due immune response towards implanted microcapsules another approach cancer suppression use angiogenesis inhibitors prevent release growth factors lead spread tumors effect implanting microcapsules loaded xenogenic cells genetically modified secrete endostatin antiangiogenic drug causes apoptosis tumor cells extensively however method local delivery microcapsules feasible treatment patients many tumors metastasis cases led recent studies involving systemic implantation murine model pancreatic cancer used study effect implanting genetically modified cytochrome expressing feline epithelial cells encapsulated cellulose sulfate polymers treatment solid approach demonstrated first time application enzyme expressing cells activate chemotherapeutic agents basis results encapsulated cell therapy product novacaps tested phase ii clinical trial treatment pancreatic cancer recently designated european medicines agency emea orphan drug europe phase iii clinical trial using product confirmed results first trial demonstrating approximate doubling survival time patients stage iv pancreatic trials using cellulose sulphate addition clear antitumour effects capsules well tolerated adverse reactions seen immune response capsules demonstrating biocompatible nature cellulose sulphate capsules one patient capsules place almost years side effects studies show promising potential application cell microcapsules towards treatment however solutions issues immune response leading inflammation surrounding tissue site capsule implantation researched detail clinical trials possible numerous studies dedicated towards development effective methods enable cardiac tissue regeneration patients ischemic heart disease emerging approach answer problems related ischemic tissue repair use stem cellbased however actual mechanism due stem cellbased therapy generative effects cardiac function still investigation even though numerous methods studied cell administration efficiency number cells retained beating heart implantation still low promising approach overcome problem use cell microencapsulation therapy shown enable higher cell retention compared injection free stem cells another strategy improve impact cell based encapsulation technique towards cardiac regenerative applications use genetically modified stem cells capable secreting angiogenic factors vascular endothelial growth factor vegf stimulate neovascularization restore perfusion damaged ischemic example shown study zang et al genetically modified xenogeneic cho cells expressing vegf encapsulated alginatepolylysinealginate microcapsules implanted rat observed encapsulation protected cells immunoresponse three weeks also led improvement cardiac tissue postinfarction due increased angiogenesis use monoclonal antibodies therapy widespread treatment cancers inflammatory diseases using cellulose sulphate technology scientists successfully encapsulated antibody producing hybridoma cells demonstrated subsequent release therapeutic antibody capsules containing hybridoma cells used preclinical studies deliver neutralising antibodies mouse retrovirus frcase successfully preventing disease many medical conditions targeted encapsulation therapies especially involving deficiency biologically derived protein one successful approaches external device acts similarly dialysis machine reservoir pig hepatocytes surrounding semipermeable portion bloodinfused apparatus remove toxins blood patients suffering severe liver failure applications still development include cells produce ciliaryderived neurotrophic factor treatment als huntingtons disease glialderived neurotrophic factor parkinsons disease erythropoietin anemia hgh addition monogenic diseases haemophilia gauchers disease mucopolysaccharide disorders could also potentially targeted encapsulated cells expressing protein otherwise lacking patient httpsenwikipediaorgwikicellencapsulation